- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.03. | Update: Rumour confirmed as MSD buys Terns for $6.7bn | ||
| 25.03. | AI in drug discovery and development: news watch | ||
| 25.03. | MSD rumoured to be nearing $6bn play for Terns Pharma | ||
| 24.03. | Karyopharm eyes Xpovio filing in myelofibrosis on mixed data | ||
| 24.03. | MSD taps Quotient for IBD drug targets in $2.2bn deal | ||
| 24.03. | AstraZeneca reportedly hit by serious cyberattack | ||
| 24.03. | Keytruda cleared for NHS use in early head and neck cancer | ||
| 24.03. | Gilead buys autoimmune disease biotech Ouro for $2.2bn | ||
| 23.03. | Sanofi pays $180m for rights to Kali autoimmune drug | ||
| 23.03. | Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss | ||
| 23.03. | FDA seeks input into 'opaque' priority voucher scheme | ||
| 23.03. | Dizal breaks new ground for EGFR drugs in lung cancer | ||
| 23.03. | Earendil raises $787m as lead TL1A antibody starts phase 2 | ||
| 20.03. | After setback, Rhythm gets good news on Imcivree from FDA | ||
| 20.03. | Novartis snaps up PI3Ka breast cancer drug in $3bn deal | ||
| 20.03. | Appeal finds NICE must reconsider Alzheimer's drugs | ||
| 20.03. | Kidney biotech R1's $78m debut, and other biofinancings | ||
| 19.03. | FDA approves higher Wegovy dose via 4th priority voucher | ||
| 19.03. | Lilly's triple agonist retatrutide passes diabetes test | ||
| 19.03. | Precision psychiatry push starts in Europe | ||
| 19.03. | Generic semaglutide in India, and other weight-loss news | ||
| 19.03. | Alfasigma claims early FDA nod for ex-GSK liver drug | ||
| 19.03. | FDA publishes advice on animal testing alternatives | ||
| 18.03. | Basecamp lifts veil on Trillion Gene Atlas genomics push | ||
| 18.03. | J&J gets FDA okay for psoriasis drug icotrokinra |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.